Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bluebird Bio Raises $60M Series D Round To Treat Rare Diseases

This article was originally published in The Pink Sheet Daily

Executive Summary

The gene therapy start-up taps diversified public and private investors, as well as strategic backer Shire, for one of the year’s biggest rounds of private capital funding for a biotech thus far.

You may also be interested in...



Bluebird’s Share Price Skyrocketing On Beta Thalassemia Optimism

On the strength of interim Phase I/II data presented at ASH and an investor presentation Dec. 10, bluebird bio is enjoying substantial growth in its stock price for the week.

Bluebird’s Improved Vector Yields Promising Early Phase II Data In Beta Thalassemia

Two patients achieve independence from transfusions and show normalizing levels of hemoglobin in Phase II trial of experimental viral vector-based gene therapy. Bluebird’s share price soared on the promising news.

Ambit IPO Ambles Out; Portola And Bluebird Prepare

Despite pricing well below its range and trading down, Ambit could raise $90 million in an IPO and a private placement with existing investors. Also this week, gene therapy company bluebird bio filed for an IPO, and hematology play Portola made the rounds on its investor road show.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS074432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel